Released May 4, 2023, after the close
10-Q filed May 4, 2023, 34 days after period end · 0000950170-23-017931
Q1 2023 · 10-Q
Revenue$0.00$0.00 no prior Q1 2022 on fileno prior Q4 2022 on file
Net Income-$18.95M-$18.95M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$4.46-$4.46 N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$19,559,000N/M
Operating Cash Flow-$23,428,000N/M
Free Cash Flowderived-$23,428,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $0.00 | — | — | $4.08M |
| Net Income | -$18.95M | -$23.09M | -$27.20M | -$26.66M |
| EPS Diluted | -$4.46 | -$0.48 | -$0.69 | -$0.76 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR